Alloy Therapeutics was last valued at $1B. It comes from the $40M Series E of Apr 2026. The company is private, so there is no listed share price.
1 valuation. The latest, $1B post-money, was set by the Series E in Apr 2026.
A private valuation is the price agreed in one transaction. The Alloy Therapeutics valuation of $1B is a private-market figure from the Series E dated 15 Apr 2026 — the whole company measured after the $40M raised in that round was already inside it. Subtract the round and the pre-money view of the same deal is $960M .
The valuation holds until the next priced round or secondary sale. A private company founded in 2011 with roughly 50 people has no daily price and no order book between rounds.
The routes section explains what is realistically available for a company at this stage.
No. Alloy Therapeutics is a private company; its shares do not trade on a public exchange.
The last valuation is $1B.
Lead investors for each round are in the funding timeline.
The closest biotech peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
